evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,062 questions · 1,113 findings · 171 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 161 · 14.5%GRADE not reported 41 · 3.7%Very low 269 · 24.2%Low 321 · 28.8%Moderate 252 · 22.6%High 69 · 6.2%

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Progression‐free survival (PSF) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower progression‐free survival (at 24 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with newly diagnosed multiple myeloma ineligible for transplant
1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Mortality within the longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower on‐study mortality (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Proportion of participants with relapse‐free survival at ≥ 12 months · adults with relapsing–remitting multiple sclerosis

Alemtuzumab 12 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

New or enlarging T2‐hyperintense lesions · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

The review found no eligible studies for this question.

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Leaving the study early · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower dropouts compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Sustained disease progression‐free survival · adults with relapsing–remitting multiple sclerosis

Alemtuzumab 12 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis

Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with new or enlarging T2‐hyperintense lesions on MRI · adults with relapsing–remitting multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Dropout · adults with relapsing–remitting multiple sclerosis

It is very uncertain whether alemtuzumab 12 mg changes dropouts Assessed by: number of participants who dropped out compared with interferon beta‐1a (very low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Proportion of participants with relapse‐free survival at ≥ 12 months · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Sustained disease progression‐free survival · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review